Fundamental Analysis of PIERIS PHARMACEUTICALS INC(NASDAQ:PIRS) stock

Fundamental Rating

PIRS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While PIRS seems to be doing ok healthwise, there are quite some concerns on its profitability. PIRS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PIRS has reported negative net income.

PIRS had a negative operating cash flow in the past year.

PIRS had negative earnings in each of the past 5 years.

In the past 5 years PIRS always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -63.43%, PIRS is not doing good in the industry: 61.54% of the companies in the same industry are doing better.

PIRS has a Return On Equity (-91.69%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-63.43%
ROE	-91.69%
ROIC	N/A

ROA(3y)-42.69%

ROA(5y)-36.72%

ROE(3y)-100.35%

ROE(5y)-95.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PIRS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PIRS does not have a ROIC to compare to the WACC, probably because it is not profitable.

PIRS has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, PIRS has less shares outstanding

There is no outstanding debt for PIRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PIRS has an Altman-Z score of -10.12. This is a bad value and indicates that PIRS is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of PIRS (-10.12) is worse than 76.92% of its industry peers.

PIRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-10.12

ROIC/WACCN/A

WACC9.12%

2.3 Liquidity

A Current Ratio of 3.24 indicates that PIRS has no problem at all paying its short term obligations.

PIRS's Current ratio of 3.24 is on the low side compared to the rest of the industry. PIRS is outperformed by 64.44% of its industry peers.

PIRS has a Quick Ratio of 3.24. This indicates that PIRS is financially healthy and has no problem in meeting its short term obligations.

PIRS's Quick ratio of 3.24 is on the low side compared to the rest of the industry. PIRS is outperformed by 63.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.24
Quick Ratio	3.24

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PIRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -776.69%.

PIRS shows a strong growth in Revenue. In the last year, the Revenue has grown by 65.26%.

The Revenue has been growing by 8.03% on average over the past years. This is quite good.

EPS 1Y (TTM)-776.69%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-3268.27%

Revenue 1Y (TTM)65.26%

Revenue growth 3Y13.45%

Revenue growth 5Y8.03%

Revenue growth Q2Q-77.79%

3.2 Future

The Earnings Per Share is expected to grow by 3.67% on average over the next years.

The Revenue is expected to grow by 42.76% on average over the next years. This is a very strong growth

EPS Next Y42.86%

EPS Next 2Y8.23%

EPS Next 3Y3.67%

EPS Next 5YN/A

Revenue Next Year-79.28%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y42.76%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PIRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PIRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y8.23%

EPS Next 3Y3.67%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PIRS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PIERIS PHARMACEUTICALS INC

NASDAQ:PIRS (5/9/2024, 7:12:18 PM)

11.16

+0.02 (+0.18%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap13.84M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-63.43%
ROE	-91.69%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.24
Quick Ratio	3.24
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-776.69%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y42.86%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)65.26%

Revenue growth 3Y13.45%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PIERIS PHARMACEUTICALS INC (PIRS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens